BioCentury | Apr 29, 2020
Emerging Company Profile

Rome: tackling repeat DNA for cancer, autoimmunity

...issued covering therapeutic modalities and diagnostic applications of repeat sequence biology Targets HERVW (ERVW-1) - Endogenous retrovirus...
BioCentury | Mar 19, 2020
Product Development

Trials, in-hospital treatments and guidances hit snags in the wake of COVID-19

...said it will provide updated guidance in its 1Q20 earnings report. Targets HERVW (ERVW-1) - Endogenous retrovirus...
BioCentury | Nov 8, 2019
Financial News

eGenesis pushes to bring pig organ transplants to humans with $100M series B

eGenesis is aiming to be the first to transplant genetically engineered pig organs into humans with its $100 million series B round, which will allow the Cambridge, Mass.-based company to advance multiple programs in parallel....
BioCentury | Nov 5, 2019
Company News

Ervaxx debuts with a new source of neoantigens

Ervaxx Ltd. emerged from stealth on Tuesday with £13 million ($16.8 million) from SV Health Investors and a platform for discovering and validating a new type of neoantigen present in the dark matter of the...
BioCentury | Oct 11, 2019
Product Development

What’s next for neoantigens

With Phase I data trickling in for first-generation vaccines, neoantigen companies are now pursuing new modalities, including cell therapy, and developing tools to expand the target space. Over a dozen companies have launched programs to...
BioCentury | Mar 12, 2019
Clinical News

GeNeuro finds path forward for temelimab in non-active progressive MS

...raises other funding. Temelimab is a humanized IgG4 mAb targeting the envelope protein of human endogenous retrovirus...
...is also in a Phase IIa trial to treat Type I diabetes. Lauren Martz, Associate Editor GNbAC1 GeNeuro S.A. Endogenous retrovirus...
BioCentury | Sep 21, 2018
Company News

Servier declines rights to GeNeuro's GNbAC1

...I diabetes. GNbAC1 is a humanized immunoglobulin (IgG4) mAb targeting the envelope protein of human endogenous retrovirus...
...1 (HERVW; ERVW-1). GeNeuro S.A. (Euronext:GNRO), Geneva, Switzerland Servier, Neuilly-sur-Seine, France Business: Autoimmune Jaime De Leon GNbAC1 GeNeuro S.A. Servier Endogenous retrovirus...
BioCentury | Aug 8, 2018
Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD); progressive supranuclear palsy (PSP) Patient sample and fly studies suggest PIWIL1 overexpression or inhibiting viral DNA polymerases could help treat AD, PSP and other tauopathies. In postmortem cortex and cerebellum samples...
BioCentury | Jun 22, 2018
Preclinical News

Blocking LSD1 could activate cancer immune response via HERV

...immunology and pathology professor Arlene Sharpe has shown inhibiting lysine-specific demethylase (LSD1; KDM1A) increases human endogenous retrovirus...
BioCentury | Mar 30, 2018
Clinical News

GeNeuro reports 12-month Phase IIb data for RRMS candidate

...22, 2017 ). GNbAC1 is a humanized IgG4 mAb targeting the envelope protein of human endogenous retrovirus...
...Jan. 11, 2016 ). GeNeuro S.A. (Euronext:GNRO), Geneva, Switzerland Product: GNbAC1 Business: Autoimmune Molecular target: Endogenous retrovirus...
...6 and 12 months and biomarkers Status: Additional Phase IIb data Milestone: NA Jaime De Leon GNbAC1 GeNeuro S.A. Servier Endogenous retrovirus...
Items per page:
1 - 10 of 52